(July 3, 2008, Shanghai) Pfizer China and NovaMed Pharmaceuticals Inc would like to emphasize that their recently announced partnership agreement seeks to facilitate Chinese patient access to established oncology products. The agreement provides NovaMed with exclusive distributional and promotional rights for six established Pfizer China’s oncology products starting in June, 2008. The agreement will allow Pfizer China to continue its focus on the growth of its new innovative oncology products in China. The six established oncology products include Adriamycin, Daunoblastina, Leucovorin, Methotrexate, Estracyt and Farlutal.
Pfizer China has chosen to partner with NovaMed because of it extensive experience and knowhow in the China market, as well as its well-developed distribution capabilities.
ABOUT NOVAMED
NovaMed Pharmaceuticals was founded in August 2005 to help global pharmaceutical companies and brand owners to achieve optimal market potential in China. Through a directly managed sales organization of 300 people strong and growing and an exclusive network of best-in-class research, development, regulatory and distribution partners, NovaMed has built viable commercialization models for products at different stages of their life cycle. These include products already commercially available in China, internationally approved products not yet registered in China, and in-license late stage development compounds. For more information, visit www.novamed.com.cn.
For more information and enquiries, please contact:
Edelman
Leslie Lin
Phone: +86 21 6289 2929 ext. 850
Mobile: +86 159 2149 3356
E-mail: Leslie.lin@edelman.com
